Entrar Registro gratuito

Edesa Biotech EPS T/T

Qual é o EPS T/T de Edesa Biotech?

O EPS T/T de Edesa Biotech, Inc. é 2.78%

Qual é a definição de EPS T/T?



A taxa de crescimento trimestral do EPS, trimestre a trimestre, é o aumento do EPS de uma empresa nos últimos 4 trimestres em comparação com o desempenho dos 4 trimestres anteriores.

The earnings per share growth rate is an important factor for judging a company's value. EPS growth rate gives a good picture of the rate at which the company has grown its profitability in respect to the total number of shares. Comparing EPS history with stock price history helps determine the most likely future direction of the stock price.

Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.

EPS T/T de empresas na Setor Health Care em NASDAQ em comparação com Edesa Biotech

O que Edesa Biotech faz?

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

Empresas com eps t/t semelhantes a Edesa Biotech